Shasun Pharmaceuticals to focus on formulations manufacturing in regulated markets

In a view to become an integrated pharmaceutical company, Shasun Pharmaceuticals is focusing on formulations manufacturing and marketing in the regulated markets. The company is expecting the share of formulations to grow from current 15% of its total revenue to 40% by 2016-17. Moreover, the company has started efforts to transform into a globally integrated pharmaceutical company from last year. Further, the company is planning to set up its marketing subsidiary in US during the current fiscal year. In Japan also, the company currently has a marketing capability for APIs, but it would be looking at how to go ahead with formulations in the country. Shasun Pharmaceuticals manufactures active pharmaceutical ingredients (APIs), their intermediates and enteric coating excipients with a significant presence in some key generics. Shasun has created a strong product portfolio, building on its R&D Expertise, regulatory capabilities and multi scale production capacities. It is one of the largest producers of Ibuprofen worldwide.